menu
    • menu
    [{"orgOrder":0,"company":"Orbit Discovery","sponsor":"WuXi AppTec","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Peptide","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Orbit Discovery \/ Orbit Discovery"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Sanegene Bio","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"RNAi-based Therapy","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Orbit Discovery","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Orbit Discovery"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Endevica Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Endevica Bio","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Endevica Bio"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Evergreen Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Evergreen Discovery","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Evergreen Discovery"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Oranomed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Oranomed","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Oranomed"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Secarna Pharma","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"Antisense Oligonucleotide-based Therapy","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"Orbit Discovery \/ Orbit Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Orbit Discovery \/ Orbit Discovery"}]

    Find Clinical Drug Pipeline Developments & Deals by Orbit Discovery

    Menu

    Orbit Discovery

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antisense Oligonucleotide-based Therapy

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : Secarna Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Secarna and Orbit Discovery Collaborate on Targeted Antisense Oligonucleotide Therapeutics

                            Details : The collaboration aims to discover and develop peptide-conjugated targeted antisense oligonucleotide (ASO) therapeutics, potentially offering new treatment options for a wider range of diseases.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            May 28, 2024

                            Lead Product(s) : Antisense Oligonucleotide-based Therapy

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : Secarna Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Oranomed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orano Med and Orbit Discovery Enter Collaboration to Discover Novel Targeted Radioligand Therapies for Cancer

                            Details : Under the terms of the collaboration, Orbit will deploy its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumours.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            September 11, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Oranomed

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : Evergreen Discovery

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orbit Discovery and Evergreen Discovery Collaborate to Discover Peptides for Targeting Radiopharmaceuticals

                            Details : The collaboration aims to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The collaboration will leverage Orbit’s peptide display technologies to find peptide leads specific to tumour related targets...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            April 03, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : Evergreen Discovery

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery

                            Sponsor : Endevica Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orbit Discovery and Endevica Bio Enter Multi-target Collaboration to Advance Development of Cachexia Therapeut...

                            Details : The collaboration aims to accelerate Endevica’s development of advanced GPCR-targeting therapeutics on receptor sets both novel and complimentary to its lead compound to creat first-in-class therapeutics for cachexia caused by cancer and other chronic ...

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            February 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery

                            Sponsor : Endevica Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNAi-based Therapy

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Recipient : Sanegene Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Orbit Discovery and SanegeneBio Collaborate to Identify Targeting Peptides for RNAi Drugs

                            Details : Through the collaboration with Orbit, Sanegene is looking to develop a portfolio of advanced RNAi based Therapies. Orbit’s proprietary technology enables the screening of large libraries of peptides using a combination of DNA encoded libraries and bead...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 05, 2023

                            Lead Product(s) : RNAi-based Therapy

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Recipient : Sanegene Bio

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Orbit Discovery

                            Europe arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : WuXi AppTec

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Orbit Discovery and WuXi AppTec Sign Agreement to Access Peptide Discovery and Optimisation Technologies

                            Details : Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its Partners obtain clinically relevant data packs and materials in a rapid time frame.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 07, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : WuXi AppTec

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth